Adherence to pharmacological smoking cessation interventions: A literature review and synthesis of correlates and barriers

Nicotine and Tobacco Research

Volumn 20, Issue 10, 2018, Pages 1163-1172

  Pacek, Lauren R ^a   Joseph McClernon, F ^a   Bosworth, Hayden B ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; CONTROLLED STUDY; EMBASE; EMTREE; HUMAN; HUMAN TISSUE; MEDICAL SUBJECT HEADINGS; MEDICATION COMPLIANCE; MEDLINE; PLASMA; REVIEW; SELF REPORT; SMOKING CESSATION; SYNTHESIS; SYSTEMATIC REVIEW; VULNERABLE POPULATION; WEB OF SCIENCE; ADMINISTRATION AND DOSAGE; HEALTH BEHAVIOR; PROCEDURES; PSYCHOLOGY; SMOKING;

VARENICLINE;

HEALTH BEHAVIOR; HUMANS; MEDICATION ADHERENCE; SELF REPORT; SMOKERS; SMOKING CESSATION; SMOKING CESSATION AGENTS; TOBACCO USE CESSATION DEVICES; VARENICLINE; VULNERABLE POPULATIONS;

EID: 85055709320     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntx210     Document Type: Review

References (91)

1. Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.
2. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014;311(2):193-194.
3. Raupach T, Brown J, Herbec A, et al. A systematic review of studies assessing the association between adherence to smoking cessation medication and treatment success. Addiction. 2014;109(1):35-43.
4. Vrijens B, De Geest S, Hughes DA, et al.; ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691-705.
5. Solberg LI, Parker ED, Foldes SS, et al. Disparities in tobacco cessation medication orders and fills among special populations. Nicotine Tob Res. 2010;12(2):144-151.
6. Zeng F, Chen CI, Mastey V, et al. Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims. Clin Ther. 2011;33(2):225-234.
7. Hays JT, Leischow SJ, Lawrence D, et al. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res. 2010;12(6):574-581.
8. Shiffman S, Ferguson SG, Rohay J, et al. Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: relationship with use and compliance. Addiction. 2008;103(8):1371-1378.
9. Swan GE, McClure JB, Jack LM, et al. Behavioral counseling and varenicline treatment for smoking cessation. Am J Prev Med. 2010;38(5):482-490.
10. Cheong YS, Ahn SH. Effect of multi-modal interventions for smoking cessation in a university setting: a short course of varenicline, financial incentives, e-mail, and short message service. Korean J Fam Med. 2010;31:355-360.
11. Burns EK, Levinson AH. Discontinuation of nicotine replacement therapy among smoking-cessation attempters. Am J Prev Med. 2008;34(3):212-215.
12. Alterman AI, Gariti P, Cook TG, et al. Nicodermal patch adherence and its correlates. Drug Alcohol Depend. 1999;53(2):159-165.
13. Lam TH, Abdullah AS, Chan SS, et al.; Hong Kong Council on Smoking and Health Smoking Cessation Health Centre (SCHC) Steering Group. Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: a preliminary investigation. Psychopharmacology (Berl). 2005;177(4):400-408.
14. Cooper TV, DeBon MW, Stockton M, et al. Correlates of adherence with transdermal nicotine. Addict Behav. 2004;29(8):1565-1578.
15. Catz SL, Jack LM, McClure JB, et al. Adherence to varenicline in th COMPASS smoking cessation intervention trial. Nicotine Tob Res. 2011;13(5):361-368.
16. Hollands GJ, Sutton S, McDermott MS, et al. Adherence to and consumption of nicotine replacement therapy and the relationship with abstinence within a smoking cessation trial in primary care. Nicotine Tob Res. 2013;15(9):1537-1544.
17. Liberman JN, Lichtenfeld MJ, Galaznik A, et al. Adherence to varenicline and associated smoking cessation in a community-based patient setting. J Manag Care Pharm. 2013;19(2):125-131.
18. Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. Addiction. 2007;102(5):809-814.
19. Kotz D, Brown J, West R. 'Real-world' effectiveness of smoking cessation treatments: a population study. Addiction. 2014;109(3):491-499.
20. DeWorsop D, Creatura G, Bluez G, et al. Feasibility and success of cellphone assisted remote observation of medication adherence (CAROMA) in clinical trials. Drug Alcohol Depend. 2016;163:24-30.
21. Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med. 1999;159(17):2033-2038.
22. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002;288(10):1260-1264.
23. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 2008.
24. Curry SJ, Ludman EJ, McClure J. Self-administered treatment for smoking cessation. J Clin Psychol. 2003;59(3):305-319.
25. Lee JY, Kim MJ, Jun HJ, et al. Adherence to varenicline and abstinence rates for quitting smoking in a private health promotion center-based smoking cessation clinic. Tuberc Respir Dis (Seoul). 2012;72(5):426-432.
26. Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009;11(3):234-239.
27. Browning KK, Wewers ME, Ferketich AK, et al. Adherence to tobacco dependence treatment among HIV-infected smokers. AIDS Behav. 2016;20(3):608-621.
28. Shelley D, Tseng TY, Gonzalez M, et al. Correlates of adherence to varenicline among HIV+ smokers. Nicotine Tob Res. 2015;17(8):968-974.
29. Ferguson SG, Shiffman S, Gitchell JG. Nicotine replacement therapies: patient safety and persistence. Patient Relat Outcome Meas. 2011;2:111-117.
30. World Health Organization. Adherence to Long Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
31. Berg CJ, Ahluwalia JS, Cropsey K. Predictors of adherence to behavioral counseling and medication among female prisoners enrolled in a smoking cessation trial. J Correct Health Care. 2013;19(4):236-247.
32. Nollen NL, Mayo MS, Ahluwalia JS, et al. Factors associated with discontinuation of bupropion and counseling among African American light smokers in a randomized clinical trial. Ann Behav Med. 2013;46(3):336-348.
33. Hawk LW Jr, Ashare RL, Lohnes SF, et al. The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial. Clin Pharmacol Ther. 2012;91(2):172-180.
34. Voci SC, Zawertailo LA, Hussain S, et al. Association between adherence to free nicotine replacement therapy and successful quitting. Addict Behav. 2016;61:25-31.
35. Rojewski AM, Fucito LM, Baldassarri S, et al. Nicotine replacement therapy use predicts smoking and drinking outcomes among heavy-drinking smokers calling a tobacco quitline. J Smok Cessat. 2016;12(2):99-104.
36. Kushnir V, Sproule BA, Cunningham JA. Mailed distribution of free nicotine patches without behavioral support: predictors of use and cessation. Addict Behav. 2017;67:73-78.
37. Scherphof CS, van den Eijnden RJ, Lugtig P, et al. Adolescents' use of nicotine replacement therapy for smoking cessation: predictors of compliance trajectories. Psychopharmacology (Berl). 2014;231(8):1743-1752.
38. Yingst JM, Veldheer S, Hrabovsky S, et al. Reasons for non-adherence to nicotine patch therapy during the first month of a quit attempt. Int J Clin Pract. 2015;69(8):883-888.
39. Cropsey KL, Clark CB, Zhang X, et al. Race and medication adherence moderate cessation outcomes in criminal justice smokers. Am J Prev Med. 2015;49(3):335-344.
40. Leischow SJ, Muramoto ML, Matthews E, et al. Adolescent smoking cessation with bupropion: the role of adherence. Nicotine Tob Res. 2016;18(5):1202-1205.
41. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91.
42. Grandi SM, Eisenberg MJ, Joseph L, et al. Cessation treatment adherence and smoking abstinence in patients after acute myocardial infarction. Am Heart J. 2016;173:35-40.
43. Hood NE, Ferketich AK, Paskett ED, et al. Treatment adherence in a lay health adviser intervention to treat tobacco dependence. Health Educ Res. 2013;28(1):72-82.
44. Okuyemi KS, Zheng H, Guo H, et al. Predictors of adherence to nicotine gum and counseling among African-American light smokers. J Gen Intern Med. 2010;25(9):969-976.
45. Cropsey KL, Clark CB, Stevens EN, et al. Predictors of medication adherence and smoking cessation among smokers under community corrections supervision. Addict Behav. 2017;65:111-117.
46. Tague C, Richter KP, Cox LS, et al. Impact of telephone-based care coordination on use of cessation medications posthospital discharge: a randomized controlled trial. Nicotine Tob Res. 2017;19(3):299-306.
47. Fish LJ, Peterson BL, Namenek Brouwer RJ, et al. Adherence to nicotine replacement therapy among pregnant smokers. Nicotine Tob Res. 2009;11(5):514-518.
48. Balmford J, Borland R, Hammond D, et al. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nicotine Tob Res. 2011;13(2):94-102.
49. Vaz LR, Aveyard P, Cooper S, et al. The association between treatment adherence to nicotine patches and smoking cessation in pregnancy: a secondary analysis of a randomized controlled trial. Nicotine Tob Res. 2016;18(10):1952-1959.
50. Ben Taleb Z, Ward KD, Asfar T, et al. Predictors of adherence to pharmacological and behavioral treatment in a cessation trial among smokers in Aleppo, Syria. Drug Alcohol Depend. 2015;153:167-172.
51. Shadel WG, Galvan FH, Tucker JS. Developing a nicotine patch adherence intervention for HIV-positive Latino smokers. Addict Behav. 2016;59:52-57.
52. Wiggers LC, Smets EM, Oort FJ, et al. Adherence to nicotine replacement patch therapy in cardiovascular patients. Int J Behav Med. 2006;13(1):79-88.
53. Ware JJ, Aveyard P, Broderick P, et al. The association of rs1051730 genotype on adherence to and consumption of prescribed nicotine replacement therapy dose during a smoking cessation attempt. Drug Alcohol Depend. 2015;151:236-240.
54. Swan GE, Valdes AM, Ring HZ, et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J. 2005;5(1):21-29.
55. de Dios MA, Anderson BJ, Stanton C, et al. Project impact: a pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino light smokers. J Subst Abuse Treat. 2012;43(3):322-330.
56. Harrison-Woolrych M, Ashton J. Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand. Pharmacoepidemiol Drug Saf. 2010;19(9):949-953.
57. de Dios MA, Stanton CA, Cano MÁ, et al. The influence of social support on smoking cessation treatment adherence among HIV+ smokers. Nicotine Tob Res. 2016;18(5):1126-1133.
58. Carroll AJ, Veluz-Wilkins AK, Blazekovic S, et al. Cancer-related disease factors and smoking cessation treatment: analysis of an ongoing clinical trial. Psychooncology. 2017. doi:10.1002/pon.4483
59. Fucito LM, Toll BA, Salovey P, et al. Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment. Psychol Addict Behav. 2009;23(2):373-379.
60. Tseng TY, Krebs P, Schoenthaler A, et al. Combining text messaging and telephone counseling to increase varenicline adherence and smoking abstinence among cigarette smokers living with HIV: a randomized controlled study. AIDS Behav. 2017;21(7):1964-1974.
61. Fogarty L, Roter D, Larson S, et al. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46(2):93-108.
62. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.
63. Schmid H, Hartmann B, Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res. 2009;14(5):185-190.
64. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother. 2004;38(2):303-312.
65. Weiner JR, Toy EL, Sacco P, et al. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother. 2008;9(5):751-766.
66. Suehs BT, Davis C, Galaznik A, et al. Association of out-of-pocket pharmacy costs with adherence to varenicline. J Manag Care Spec Pharm. 2014;20(6):592-600.
67. van Boven JF, Vemer P. Higher adherence during reimbursement of pharmacological smoking cessation treatments. Nicotine Tob Res. 2016;18(1):56-63.
68. Schmitz JM, Sayre SL, Stotts AL, et al. Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback. J Behav Med. 2005;28(2):139-147.
69. Tucker JS, Shadel WG, Galvan FH, et al. Pilot evaluation of a brief intervention to improve nicotine patch adherence among smokers living with HIV/AIDS. Psychol Addict Behav. 2017;31(2):148-153.
70. Mooney ME, Leventhal AM, Hatsukami DK. Attitudes and knowledge about nicotine and nicotine replacement therapy. Nicotine Tob Res. 2006;8(3):435-446.
71. Jones DL, McPherson-Baker S, Lydston D, et al. Efficacy of a group medication adherence intervention among HIV positive women: the SMART/ EST Women's Project. AIDS Behav. 2007;11(1):79-86.
72. Mini KV, Ramesh A, Parthasarathi G, et al. Impact of a pharmacist provided education on medication adherence behaviour in HIV/AIDS patients treated at a non-government secondary care hospital in India. J AIDS HIV Res. 2012;4(4):94-99.
73. Goujard C, Bernard N, Sohier N, et al. Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003;34(2):191-194.
74. Bosworth HB, Granger BB, Mendys P, et al. Medication adherence: a call for action. Am Heart J. 2011;162(3):412-424.
75. Vervloet M, Linn AJ, van Weert JC, et al. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc. 2012;19(5):696-704.
76. Dunbar-Jacob J, Rohay JM. Predictors of medication adherence: fact or artifact. J Behav Med. 2016;39(6):957-968.
77. Hollands GJ, McDermott MS, Lindson-Hawley N, et al. Interventions to increase adherence to medications for tobacco dependence. Cochrane Database Syst Rev. 2015;2:CD009164.
78. Epperson CN, Toll B, Wu R, et al. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug Alcohol Depend. 2010;112(1-2):1-8.
79. Bosworth HB. Medication treatment adherence. In: Bosworth HB, Oddone EZ, Weinberger M, eds. Patient Treatment Adherence: Concepts, Interventions, and Measurement. New York, NY: Routledge; 2006:147-194.
80. Buchanan TS, Berg CJ, Cox LS, et al. Adherence to varenicline among African American smokers: an exploratory analysis comparing plasma concentration, pill count, and self-report. Nicotine Tob Res. 2012;14(9):1083-1091.
81. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331-342.
82. Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15(7):1381-1396.
83. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414-2419.
84. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes melli-tus. Arch Intern Med. 2006;166(17):1836-1841.
85. Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56(5):727-734.
86. Hser YI, McCarthy WJ, Anglin MD. Tobacco use as a distal predictor of mortality among long-term narcotics addicts. Prev Med. 1994;23(1):61-69.
87. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA. 1996;275(14):1097-1103.
88. Goodwin RD, Pagura J, Spiwak R, et al. Predictors of persistent nicotine dependence among adults in the United States. Drug Alcohol Depend. 2011;118(2-3):127-133.
89. Le Strat Y, Rehm J, Le Foll B. How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. Tob Control. 2011;20(5):338-343.
90. Matza LS, Yu-Isenberg KS, Coyne KS, et al. Further testing of the reliability and validity of the ASK-20 adherence barrier questionnaire in a medical center outpatient population. Curr Med Res Opin. 2008;24(11):3197-3206.
91. Horne R, Chapman SC, Parham R, et al. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8(12):e80633.